Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Clin Mol Hepatol. 2014 Dec;20(4):347-354. English. Original Article. https://doi.org/10.3350/cmh.2014.20.4.347
Cho HJ , Kim SS , Ahn SJ , Park JH , Kim DJ , Kim YB , Cho SW , Cheong JY .
Department of Gastroenterology, Hallym University College of Medicine, Chuncheon, Korea. jaeyoun620@gmail.com
Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.
Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
Abstract

BACKGROUND/AIMS: Transferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B. METHODS: The study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared. RESULTS: Univariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B. CONCLUSIONS: Serum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.

Copyright © 2019. Korean Association of Medical Journal Editors.